BCIQ Profiles

Company Profile Report

Bug-brain axis

Why Axial is targeting the gut microbiome to treat CNS disorders

Investors supplied Axial Biotherapeutics Inc. with enough cash to get human proof of concept showing that correcting microbiome imbalances can treat pathologies and symptoms of neurological disorders.

The newco debuted Nov. 30 with a $19.2 million series A co-led by Longwood Fund and

Read the full 425 word article

How to gain access

Continue reading with a
two-week free trial.